Exon 20 News Today

Expert oncologist Alex Spira, MD, PhD, FACP, shares his excitement for an upcoming program centered on the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.

1. Median progression-free survival was 11.4 months in the amivantamab–chemotherapy group and 6.7 months in the chemotherapy group with HR 0.40. 2. Serious adverse events occurred in 37% of the amivantamab–chemotherapy group and 31% of the chemotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Exon 20 insertions are the third most common mutation in